🏛️ Verified NIH Record • Updated 2026-04-17
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (NCT05972135)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: SCRI Development Innovations, LLC
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- Arizona Oncology Associates — Tucson, Arizona
- Colorado Blood Cancer Institute — Denver, Colorado
- Rocky Mountain Cancer Center — Denver, Colorado
- Medical Oncology Hematology Consultants — Newark, Delaware
- Florida Cancer Specialists — Lake Mary, Florida
- Maryland Oncology Hematology — Columbia, Maryland
- Minnesota Oncology Hematology — Minneapolis, Minnesota
- Virginia Oncology Associates — Elizabeth City, North Carolina
- Oncology Hematology Care — Cincinnati, Ohio
- Oncology Associates of Oregon — Eugene, Oregon
- TriStar Bone Marrow Transplant — Nashville, Tennessee
- Vanderbilt- Ingram Cancer Center — Nashville, Tennessee
- Texas Oncology — Austin, Texas
- Texas Oncology - San Antonio — San Antonio, Texas
- Texas Oncology - Northeast Texas — Tyler, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Blue Ridge Cancer Center — Roanoke, Virginia
📞 Contact the Study Coordinator
Phone: (844) 710-6157
Email: SCRI.InnovationsMedical@scri.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.